Literature DB >> 24119636

Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?

Robert C Goldman1.   

Abstract

High through put screening (HTS) was extensively used in attempts to discover new TB drugs from libraries of pure small molecule compounds many of which complied with the rule of five. Coupled with new methods for determining the target of lead compounds by resistance selection followed by genome sequencing, screening for growth inhibitors led to several recent reports of compounds linked to specific antitubercular targets. This systematic approach to drug discovery appears at present to select for small, hydrophobic molecules affecting the function of essential membrane proteins, for example DprE, MmpL3, AtpE, QcrB, and Pks13. All of these molecules possessed bactericidal activity in vitro. Mutations in GlpK were also selected with hydrophobic compounds identified by screening for growth inhibitors. The chemical properties of the compounds reported are considered in the context of uptake and possible mechanisms of inhibition of membrane bound targets based on other model systems (e.g. cardiovascular drugs affecting voltage-gated L-type calcium channels, daptomycin, telavancin, gramicidin S, and role of boundary lipids). The relationship between hydrophobicity, compound uptake, and mode of action are addressed. Compared to the average calculated logP for approved TB drugs of -1.0, the average for these hydrophobic compounds is 4.0 representing a major shift in hydrophobicity of 5 orders of magnitude. Furthermore several hydrophobic compounds in the Prestwick Chemical Library (FDA approved drugs) inhibit growth of M. tuberculosis at 10 μg/ml or less and have an average calculated logP of 5.7 signaling caution with respect to specificity. Key recommendations are made regarding follow-up of the hydrophobic leads recently discovered using phenotypic screening and target elucidation by genome sequencing. Consideration is also given to the properties of small molecule screening libraries, the types of molecules and targets recently discovered as antitubercular leads and compliance with the rule of 5.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antitubercular drugs; Genetic analysis; High throughput screening; Hydrophobic compounds; Membrane targets

Mesh:

Substances:

Year:  2013        PMID: 24119636     DOI: 10.1016/j.tube.2013.09.003

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  40 in total

1.  Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.

Authors:  Giovanni Piccaro; Giovanna Poce; Mariangela Biava; Federico Giannoni; Lanfranco Fattorini
Journal:  J Antibiot (Tokyo)       Date:  2015-05-06       Impact factor: 2.649

Review 2.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

Review 3.  Peptidoglycan in Mycobacteria: chemistry, biology and intervention.

Authors:  Tripti Raghavendra; Saniya Patil; Raju Mukherjee
Journal:  Glycoconj J       Date:  2018-09-19       Impact factor: 2.916

4.  Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis.

Authors:  Kriti Arora; Bernardo Ochoa-Montaño; Patricia S Tsang; Tom L Blundell; Stephanie S Dawes; Valerie Mizrahi; Tracy Bayliss; Claire J Mackenzie; Laura A T Cleghorn; Peter C Ray; Paul G Wyatt; Eugene Uh; Jinwoo Lee; Clifton E Barry; Helena I Boshoff
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 5.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

Authors:  Daniel T Hoagland; Jiuyu Liu; Robin B Lee; Richard E Lee
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

Review 6.  The future for early-stage tuberculosis drug discovery.

Authors:  Edison S Zuniga; Julie Early; Tanya Parish
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

7.  Drug development: Locking down metabolism.

Authors:  William R Bishai
Journal:  Nat Chem Biol       Date:  2017-08-18       Impact factor: 15.040

8.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.

Authors:  Peter C Ray; Margaret Huggett; Penelope A Turner; Malcolm Taylor; Laura A T Cleghorn; Julie Early; Anuradha Kumar; Shilah A Bonnett; Lindsay Flint; Douglas Joerss; James Johnson; Aaron Korkegian; Steven Mullen; Abraham L Moure; Susan H Davis; Dinakaran Murugesan; Michael Mathieson; Nicola Caldwell; Curtis A Engelhart; Dirk Schnappinger; Ola Epemolu; Fabio Zuccotto; Jennifer Riley; Paul Scullion; Laste Stojanovski; Lisa Massoudi; Gregory T Robertson; Anne J Lenaerts; Gail Freiberg; Dale J Kempf; Thierry Masquelin; Philip A Hipskind; Joshua Odingo; Kevin D Read; Simon R Green; Paul G Wyatt; Tanya Parish
Journal:  ACS Omega       Date:  2021-01-13

9.  Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery.

Authors:  Krupa Naran; Atica Moosa; Clifton E Barry; Helena I M Boshoff; Valerie Mizrahi; Digby F Warner
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

10.  Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis.

Authors:  Sean Ekins; Joel S Freundlich; Robert C Reynolds
Journal:  J Chem Inf Model       Date:  2014-07-17       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.